|
Sales of Crestor in Japan to Exceed ¥100 Bil.
|
p 1 |
|
Merck Serono to Increase Market Share for Gonalef, Saizen
|
p 3 |
|
Blopress Remains No. 1 for 6 Terms in a Row: Domestic Drugs Sales Ranking |
p 4 |
|
Rate of New Premium for New Drug Development Will Be 5.10% |
p 9 |
|
Flu Vaccines from GSK, Novartis Receive First "Emergency Approval" | p 12 |
|
Nichi-Iko to Enter the Market for Biosimilars: President Tamura |
p 14 |
|
Latanoprost to See Generics from 23 Companies |
p 15 |
|
Eisai to Apply for Eribulin in Japan, the US and Europe in March |
p 16 |
|
Abbott's Everolimus-Eluting Stent XIENCE V Approved in Japan |
p 17 |
